Ironwood Pharmaceuticals (IRWD): רווח נקי למניה ב-12 החודשים האחרונים

Ironwood Pharmaceuticals (IRWD) demonstrates high margins due to partner distribution, which eliminates capital expenditures. The rolling net income per share visualizes this efficiency, where the value 0.89 represents the current metric. A growing patient base driven by expanded FDA guidelines strengthens the ecosystem, while patent protection for the core drug guarantees the company stable revenue for years to come.
פילוחים אנליטיים ודוחות נתונים של חברת Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (IRWD) maintains its leadership in GI therapy driven by global demand for its irritable bowel syndrome medication. This success is reflected in the TTM earnings per share chart, which calculates net income per share over a year, allowing investors to objectively assess real business efficiency and return on capital without the influence of quarterly fluctuations.